Triple-positive breast carcinoma
MONDO:0700078A breast carcinoma which is positive for expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).
Also known as: HR-positive HER2 positive breast cancer, hormone receptor positive her2 positive breast cancer, triple positive breast cancer
2827 clinical trials for this condition and its sub-types, 33 tagged with Triple-positive breast carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can a drug combo replace chemo before breast cancer surgery?
Disease control Not yet recruitingThis phase II trial tests whether a combination of culmerciclib, letrozole, trastuzumab, and pertuzumab can shrink tumors before surgery in people with HR-positive, HER2-positive early or locally advanced breast cancer. About 33 participants who have not had prior treatment will …
Phase 2 • Sponsor: Shengjing Hospital • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could a targeted drug re-sensitize resistant breast cancer?
Disease control Not yet recruitingThis pilot trial tests whether adding the drug alisertib to usual care can help people with advanced HR+/HER2+ breast cancer whose disease has become resistant to standard treatments. Researchers want to see if alisertib can block communication between hormone receptors and HER2,…
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug sequence aims to outsmart advanced breast cancer
Disease control Not yet recruitingThis trial tests a planned sequence of treatments for people with advanced or metastatic HER2-positive and hormone receptor-positive breast cancer. Participants first receive T-DXd (Enhertu) plus pertuzumab, then switch to a maintenance combination of palbociclib, endocrine thera…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer
Disease control Not yet recruitingThis study tests whether adding a new oral drug called fulvestaciclib to standard anti-HER2 and hormone therapy can help people with HR+/HER2+ advanced breast cancer live longer without their disease getting worse. Some participants receive the combo after initial chemotherapy, w…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for advanced breast cancer? Triple-Drug combo tested after key therapy fails
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs (neratinib, fulvestrant, and eribulin) in 35 women with a specific type of advanced breast cancer (HR+/HER2+) that has stopped responding to the drug trastuzumab deruxtecan. The goal is to see if this new combination can shrin…
Phase 2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug duo aims to wipe out breast cancer before surgery
Disease control Not yet recruitingThis study tests a new drug combination (SHR-A1811 plus pertuzumab) given before surgery to women with early or locally advanced HR-positive, HER2-positive breast cancer. The goal is to see if this treatment can eliminate all cancer cells in the breast and lymph nodes by the time…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Tailored drug combo aims to boost breast cancer remission before surgery
Disease control Not yet recruitingThis phase 2 trial tests a personalized approach for women with early-stage HR+/HER2+ breast cancer. After two cycles of standard therapy, patients who respond well continue the same treatment, while those who do not switch to a combination of targeted therapy and hormone-blockin…
Phase 2 • Sponsor: The First Affiliated Hospital of Bengbu Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug cocktail aims to wipe out Triple-Positive breast tumors before surgery
Disease control Not yet recruitingThis study is testing a combination of four drugs (trastuzumab, pertuzumab, palbociclib, and exemestane) given before surgery to 90 people with early-stage triple-positive breast cancer. The goal is to see if this treatment can completely eliminate cancer cells in the breast and …
Phase 2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New breast cancer cocktail aims to ditch chemo before surgery
Disease control Not yet recruitingThis phase II trial tests a combination of targeted drugs and hormone therapy given before surgery for a specific type of breast cancer (ER-positive, HER2-positive). The goal is to shrink tumors without using standard chemotherapy. The study will enroll 42 women and measure how m…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Chemo-Free hope: new drug combo may spare thousands from toxic treatment
Disease control Not yet recruitingThis study tests whether a combination of targeted drugs and hormone therapy can replace chemotherapy for people with a specific type of early-stage breast cancer (HR-positive, HER2-positive, no lymph node spread). About 1,500 participants will receive either the standard chemo p…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC